Dr. Pieczonka on where sabizabulin (VERU-111) fits in the mCRPC paradigm
Christopher Pieczonka, MD, director of clinical research, Crouse Health, discusses where the novel agent sabizabulin (VERU-111) would fit in the metastatic castration-resistant prostate cancer (mCRPC) paradigm if it succeeds in an ongoing phase 3 trial (NCT04844749). The study is exploring single-agent sabizabulin as a second-line treatment for patients with mCRPC.
In the video, Pieczonka says that if sabizabulin is established as a second-line option, it would then be explored in the upfront setting, most likely in combination regimens. Positive phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in mCRPC were presented during the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi: 10.1200/JCO.2021.39.15_suppl.5056).
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
